



BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

Regd. Office : 11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015. Fax : 0731-2723017
Tel. : 0731-2723016, 4066216 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com
Factory : Plot No. 8, Sector - IV, Kheda Industrial Area, Pithampur Distt. Dhar (M.P.)

Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)
Tel. : 0731-2426700, 2426718, 2524003, Fax : 0731-2426726 • CIN : L24233MP1985PLC002709

Date: 30/05/2018

To, The Company Secretary, Corporate Compliance Department The National Stock Exchange of India Limited Bandra Kurla Complex, Mumbai	To, The Company Secretary Corporate Compliance Department BSE Limited Dalal Street, P.J. Tower, Mumbai
--	--

Sub:- Submission of Audited Financial Results for the Quarter as well as year ended 31st March, 2018 in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref:- Scrip Code: 524396; NSE Symbol: BIOFILCHEM; ISIN: INE829A01014

Dear Sir/Madam,

This is in continuation of our letter dated 23rd May, 2018 regarding information of Board Meeting for consideration and approval of Audited Financial Results for the quarter as well as year ended 31st March, 2018.

In compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to submit the Audited Financial Results for the quarter as well as year ended 31st March, 2018 duly approved by the Board at its meeting held on today Wednesday, 30th May, 2018, together with Auditors Report thereon, Statement of assets and liabilities and declaration by the Managing Director of the Company pursuant to second proviso of Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Further above results shall also be submitted in XBRL mode (Excel Template provided by Exchange) within 24 hours from the conclusion of Board Meeting.


The aforesaid results will be published in one Hindi (vernacular) and widely circulated English Newspaper. These results shall also be uploaded on the Company's website www.biofilgroup.net and on the website of the Stock Exchange at www.bseindia.com and www.nseindia.com.

The meeting of the Board of directors was commenced at 5.00 P.M and concluded at 6.40 P.M.

Thanking You,

Yours faithfully

For Biofil Chemicals and Pharmaceuticals Limited


Ramesh Shah
Managing Director
DIN: 00028819





BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

Regd. Office : 11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015. Fax : 0731-2723017
Tel. : 0731-2723016, 4066216 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com
Factory : Plot No. 8, Sector - IV, Kheda Industrial Area, Pithampur Distt. Dhar (M.P.)

Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)
Tel. : 0731-2426700, 2426718, 2524003, Fax : 0731-2426726 • CIN : L24233MP1985PLC002709

Date 30/05/2018

To,
The Secretary,
Corporate Relationship Department,
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers, Dalal Street Fort,
Mumbai 400001

To,
The Secretary,
Corporate Compliance Department,
The National Stock Exchange of India Limited
Bandra Kurla Complex, Mumbai

Sub.; Submission of declaration regarding unmodified opinion of the Auditors on Annual Audited Financial Results of the Company for the year ended 31st March, 2018 as per second proviso to Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015.

Ref: BSE Scrip Code: 524396; NSE Symbol: BIOFILCHEM; ISIN: INE829A01014


Dear Sir/Madam,

DECLARATION

Pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time, I, the undersigned do hereby declare that in the Audit Report accompanying the Annual Audited Financial Statements of **Biofil Chemicals and Pharmaceuticals Limited** for the financial year ended on **31st March, 2018**, the Statutory Auditor did not express any modified opinion/audit qualification or other reservation and accordingly, the Statement on Impact of Audit Qualifications is not required to be given.

You are requested to please consider and take on record the same.

For Biofil Chemicals and Pharmaceuticals Limited


Ramesh Shah
Managing Director
DIN 00028819





Auditor's Report On Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors
Biofil Chemicals and Pharmaceuticals Limited

We have audited the quarterly financial results of **Biofil Chemicals and Pharmaceuticals Limited** for the quarter ended on 31st March, 2018 and the year to date results for the year from 1st April, 2017 to 31st March, 2018, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standards notified under Section 133 of the Companies Act, 2013 read with relevant Rules issued there under or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We have conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as year to date financial results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular dated 05th July, 2016 in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the quarter ended 31st March, 2018 as well as year to date results for the year from 01st April, 2017 to 31st March 2018.


For Maheshwari & Gupta
Chartered Accountants
FRN: 006179C

CA Sunil Maheshwari
Partner

M No: 403346

Place: Indore

Date: 30th May 2018



Audited Financial Results of Quarter and Year Ended of 31st March, 2018
Biofil Chemicals and Pharmaceuticals Limited
 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)


CIN L24233MP1985PLC002709

Email Id:bcplcompliance@gmail.com Phone No. 0731-2426718, 2723016-17

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st March 2018

(Amount in Lakhs except EPS)

Statement of Audited Financial Results for the Quarter and Year ended 31st March 2018						
Particulars	3 months ended (31/03/2018)	Preceding 3 months ended (31/12/2017)	Corresponding 3 months ended in the previous year (31/03/2017)	Audited for the year ended March 31 2017	Audited for the year Ended March 31 2018	
	Audited	Reviewed	Audited	Audited	Audited	
I Revenue from Operation	355.18	91.11	625.66	1347.74	1236.00	
II Other Income	5.37	3.69	8.04	11.49	10.07	
III Total Revenue (I + II)	360.55	94.80	633.70	1359.23	1246.07	
IV Expenses						
(a) Cost of materials consumed	38.88	13.15	30.22	90.41	77.75	
(b) Purchases of stock-in-trade	278.08	14.18	330.93	762.02	991.06	
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(85.80)	0.50	16.03	(1.32)	(91.70)	
(d) Employee benefits expense	31.89	18.01	25.40	53.22	72.93	
(e) Finance Cost	3.68	3.77	5.11	16.36	15.06	
(f) Depreciation and Amortisation Expense	8.30	7.11	8.85	28.42	29.63	
(g) Other expenses	66.03	15.73	65.23	179.08	92.53	
Total expenses (IV)	341.05	72.44	481.78	1128.19	1187.25	
V Profit/ (Loss) before exceptional items and tax (III-IV)	19.49	22.35	151.92	231.04	58.82	
VI Exceptional Items	0.00	0.00	1.62	0.00	0.00	
VII Profit/ (Loss) before tax (V - VI)	19.49	22.35	150.30	231.04	58.82	
VIII Tax expense:						
(1) Current tax						
(2) Deferred tax Credit/(Charge)	11.75	0.00	50.00	51.62	11.75	
IX Profit/(Loss) for the period from continuing operation (VII-VIII)	0.00	0.00	0.00	0.00	0.00	
X Profit/(Loss) for the period for dis-continued operation	7.74	22.35	100.30	179.42	47.07	
XI Tax expenses of discontinued operation	0.00	0.00	0.00	0.00	0.00	
XII Profit/(Loss) for the period for dis-continued operation after tax (X-XI)	0.00	0.00	0.00	0.00	0.00	
XIII Profit/ (Loss) for the period (IX+XII)	0.00	0.00	0.00	0.00	0.00	
XIV Other Comprehensive Income	7.74	22.35	100.30	179.42	47.07	
A) (i) Items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	
(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	
B) (i) Items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	
(ii) Income Tax relating to items that will be reclassified to Profit or Loss						
c) Other Comprehensive Income (net of tax)	0.00	0.00	0.00	0.00	0.00	
XV Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit or Loss and other Comprehensive income for the period)	7.74	22.35	100.30	179.42	47.07	
XVI Paid-Up equity share capital (face value of Rs 10/- each)	1627.38	1627.38	1627.38	1627.38	1627.38	
XVIII Earnings per equity shares (for continuing operation):						
(1) Basic (Rs)	0.05	0.14	0.62	1.10	0.28	
(2) Diluted (Rs)	0.05	0.14	0.62	1.10	0.28	



1. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules 2015 (Ind As) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning April 1, 2017, the Company has for the first time adopted Ind AS with a transition date of April 1, 2016.
2. The above audited financial results of the company for the quarter and year ended March 31, 2018 were reviewed by the Audit committee and approved by the Board of Directors at their meeting held on May 30, 2018.
3. The above Audited financial Results of the Quarter and Year ended 31st March 2018 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015, has been carried out by the Statutory Auditors.
4. The Company has reported segment wise information as per Indian Accounting Standard (Ind AS-108). The Operations of the Company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments
 1. Pharma Product
 2. Chemicals Division
 3. Plastic Division

5. The reconciliation of net profit or loss reported in accordance with Indian GAAP to total comprehensive income in accordance with Ind As is given below.

Particulars	Quarter Ended	Year Ended
	Audited	Audited
	31.03.2017	31.03.2017
Total Income / Revenue From Operations	633.70	1359.23
Net Profit for the period before tax (before Exceptional and/or Extraordinary items)	151.92	231.04
Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	150.30	231.04
Net Profit for the period after tax	100.30	179.42
Total Comprehensive Income for the period {Comprising Profit for the period after Tax and Other	100.30	179.42
Paid up Equity Share Capital	1627.38	1627.38
Earning Per Share in Rs. (Per Share of Rs. 10 each, Basic & Basic	0.62	1.10
Diluted	0.62	1.10

6. Reconciliation of the other equity with those reported under previous (GAAP) is s under:

Particulars	Year ended
	31.03.2017(Audited)
Other Equity (reserves & Surplus) as per Previous GAAP	(357.725)
Discounting /Unwinding of liability / provision	0
Gain/(Loss) on fair value of investments	0
Deferred Tax on unrealized profits	0
Others	0
Other equity (Reserves & Surplus)	(357.725)

7. The aforesaid audited financial Results will be uploaded on the Company's website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors

8. Previous year figures are regrouped/ reclassified to confirm the current years presentation.

9. The figures of the last quarter are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year.

Date : 30/05/2018
Place : Indore

FOR Biofil Chemicals & Pharmaceuticals Limited



RAMESH SHAH
MANAGING DIRECTOR
(DIN: 00028819)



BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.
CIN L24233MP1985PLC002709

Segmentwise Revenue, Results and Capital Employed for year ended 31st March -2018

S.No.	Segment Revenue	(Amount in Lakhs)				
		Quarter Ended			Year Ended	
		March 31, 2018 Audited	December 31, 2017 Reviewed	March 31, 2017 Audited	31 March 2018 Audited	31 March 2017 Audited
1	Segment Revenue					
	Pharma Unit	301.03	36.58	662.49	1,053.13	1,205.08
	Chemicals Division	54.14	54.53	41.23	180.02	139.08
	Plastic Division	0.00	0.00	0.28	2.84	1.28
	Other	5.37	3.69	(70.30)	10.07	13.79
	Gross Turnover	360.55	94.80	633.70	1,246.07	1,359.23
2	Segment Results					
	Pharma Unit	30.78	8.30	156.00	56.31	252.24
	Chemicals Division	(6.55)	21.55	(29.57)	26.91	(21.46)
	Plastic Division	4.40	(3.75)	6.72	(4.01)	(7.26)
	Other	(8.41)	0.00	19.84	(8.41)	19.84
	Total Segment Profit Before Tax	20.22	26.10	152.99	70.79	243.36
	Interest Income	3.03	0.00	2.69	3.03	2.69
	Interest Expenses	3.75	3.75	3.76	15.00	15.01
	Other Unallocable Income net of Expenditure					
	Profit Before Tax	19.49	22.35	151.92	58.82	231.04
	Provision for current tax	11.30	0.00	50.00	11.30	50.00
	Item Related Earlier Year	0.45	0.00	1.62	0.45	1.62
	Profit After Tax	7.75	22.35	100.30	47.07	179.42
3	Capital Employed					
	Segment Assets (A)					
	Pharma Division	1,485.86	1,417.27	1,309.64	1,485.86	1,309.64
	Chemicals Division	866.71	854.12	802.50	866.71	802.50
	Plastic Division	62.89	67.88	71.90	62.89	71.90
	Other					
	Total (A)	2,415.46	2,339.26	2,184.04	2,415.46	2,184.04
	Segment Liabilities (B)					
	Pharma Division	898.26	874.91	703.01	898.26	703.01
	Chemicals Division	41.52	40.47	66.53	41.52	66.53
	Plastic Division	158.96	152.24	144.85	158.96	144.85
	Other					
	Total (B)	1,098.74	1,067.61	914.38	1,098.74	914.38
	Total Capital Employed (Segment Assets- Segment Liabilities)					
	Pharma Division	587.60	542.36	606.63	587.60	606.63
	Chemicals Division	825.19	813.65	735.97	825.19	735.97
	Plastic Division	(96.07)	(84.36)	(72.95)	(96.07)	(72.95)
	Other	0.00	0.00	0.00	0.00	0.00
	Total Capital Employed (Segment Assets- Segment Liabilities)	1,316.73	1,271.65	1,269.65	1,316.73	1,269.65

DATE : 30/05/2018
PLACE : INDORE

BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.
INDORE
RAMESH SHAH
MANAGING DIRECTOR
DIN: 00028819

BIOFIL CHEMICALS and PHARMACEUTICALS Ltd.
AUDITED FINANCIAL STATEMENT OF ASSETS AND LIABILITIES AS AT 31-03-2018
CIN L24233MP1985PLC002709

		(Rs. In Lacs)	
Particulars	As at 31/03/2018	As at 31/03/2017	
A ASSETS			
1 Non-current assets:			
(a) Property, Plant & Equipment	924.684	916.453	
(b) Capital work in Progress			
(c) Other Intangible Assets			
(d) Financial Assets:			
i. Investments			
ii. Trade Receivables			
iii. Loans			
(e) Other Non- Current Assets			
Sub-total - Non-current assets	924.684	916.453	
2 Current assets			
(a) Inventories	102.484	16.630	
(b) Financial Assets:			
(i) Trade receivables	1,298.082	1,146.441	
(ii) Cash and cash equivalents	10.712	7.482	
(iii) Bank balances other than (ii) above	26.739	23.485	
(iv) Loans			
(v) Others (to be specified)			
(c) Current Tax Asset (Net)			
(d) Other Currents Assets	52.759	73.548	
Sub-total - Current assets			
TOTAL - ASSETS	2,415.461	2,184.039	
B EQUITY AND LIABILITIES			
1 Equity			
(i) Equity Share Capital	1,627.380	1,627.380	
(ii) Other Entity	(310.655)	(357.725)	
Sub-total- Equity	1,316.725	1,269.655	
2 Non-current Liabilities :			
a Financial Liabilities			
(i) Borrowings			
(ii) other Financial Liabilities			
b Provisions			
c Deferred tax liabilities (net)			
d Other Non-current Liabilities			
Sub-total - Non-current liabilities	1,316.725	1,269.655	
3 Current liabilities			
a Financial Liabilities			
(i) Borrowings	155.855	142.809	
(ii) Trade Payables	914.169	709.522	
(iii) other Financial Liabilities	17.411	12.053	
b Other Current Liabilities			
c Provisions	11.300	50.000	
d Current Tax Liabilities (Net)			
Sub-total - Current liabilities	1,098.735	914.384	
TOTAL - EQUITY AND LIABILITIES	2,415.461	2,184.039	

Date: 30/05/2018
Place: INDORE

BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

RAMESH SHAH
MANAGING DIRECTOR
(DIN 00028819)

